Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,211 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome - a report from the SFCE & CCLG groups.
Shankar AG, Roques G, Kirkwood AA, Lambilliotte A, Freund K, Leblanc T, Hayward J, Abbou S, Ramsay AD, Schmitt C, Gorde-Grosjean S, Pacquement H, Haouy S, Boudjemaa S, Aladjidi N, Hall GW, Landman-Parker J. Shankar AG, et al. Among authors: schmitt c. Br J Haematol. 2017 Apr;177(1):106-115. doi: 10.1111/bjh.14518. Epub 2017 Feb 21. Br J Haematol. 2017. PMID: 28220934 Free article.
Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Société Française de Lutte contre le Cancer des Enfants et des Adolescents (SFCE).
Gorde-Grosjean S, Oberlin O, Leblanc T, Pacquement H, Donadieu J, Lambilliotte A, Schell M, Dommange F, Munzer M, Paillard C, Schmitt C, Lutz P, Edan C, Ansoborlo S, Stephan JL, Michel G, Thomas C, Perel Y, Robert A, Landman-Parker J. Gorde-Grosjean S, et al. Among authors: schmitt c. Br J Haematol. 2012 Sep;158(5):649-56. doi: 10.1111/j.1365-2141.2012.09199.x. Epub 2012 Jul 4. Br J Haematol. 2012. PMID: 22757721 Free article.
Should treatment of ALK-positive anaplastic large cell lymphoma be stratified according to minimal residual disease?
Rigaud C, Abbas R, Grand D, Minard-Colin V, Aladjidi N, Buchbinder N, Garnier N, Plat G, Couec ML, Duplan M, Lambilliotte A, Schmitt C, Leblanc T, Lamant L, Brugières L. Rigaud C, et al. Among authors: schmitt c. Pediatr Blood Cancer. 2021 Jun;68(6):e28982. doi: 10.1002/pbc.28982. Epub 2021 Mar 9. Pediatr Blood Cancer. 2021. PMID: 33687135
Acute Myeloid Leukemia With Central Nervous System Involvement in Children: Experience From the French Protocol Analysis ELAM02.
Felix A, Leblanc T, Petit A, Nelkem B, Bertrand Y, Gandemer V, Sirvent A, Paillard C, Schmitt C, Rohrlich PS, Fenneteau O, Ragu C, Michel G, Auvrignon A, Baruchel A, Leverger G. Felix A, et al. Among authors: schmitt c. J Pediatr Hematol Oncol. 2018 Jan;40(1):43-47. doi: 10.1097/MPH.0000000000001034. J Pediatr Hematol Oncol. 2018. PMID: 29189507 Clinical Trial.
Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol.
Gandemer V, Pochon C, Oger E, Dalle JH, Michel G, Schmitt C, de Berranger E, Galambrun C, Cavé H, Cayuela JM, Grardel N, Macintyre E, Margueritte G, Méchinaud F, Rorhlich P, Lutz P, Demeocq F, Schneider P, Plantaz D, Poirée M, Bordigoni P. Gandemer V, et al. Among authors: schmitt c. Br J Haematol. 2014 May;165(3):392-401. doi: 10.1111/bjh.12749. Epub 2014 Jan 30. Br J Haematol. 2014. PMID: 24479958 Free article. Clinical Trial.
Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
Zwaan CM, Kowalczyk J, Schmitt C, Bielorai B, Russo MW, Woessner M, Ranganathan S, Leverger G. Zwaan CM, et al. Among authors: schmitt c. Br J Haematol. 2017 Oct;179(2):284-293. doi: 10.1111/bjh.14874. Epub 2017 Aug 2. Br J Haematol. 2017. PMID: 28771663 Free article. Clinical Trial.
A multicentric randomized phase II clinical trial evaluating high-dose thiotepa as adjuvant treatment to standard chemotherapy in patients with resectable relapsed osteosarcoma.
Marec-Berard P, Dalban C, Gaspar N, Brugieres L, Gentet JC, Lervat C, Corradini N, Castex MP, Schmitt C, Pacquement H, Tabone MD, Brahmi M, Metzger S, Blay JY, Pérol D; OSII Thiotepa study group of the French Society of Pediatric Cancer - La Société Française des Cancers de l’Enfant (SFCE) and the French Sarcoma Group–Groupe d’Etude des Tumeurs Osseuses (GSF-GETO) Networks. Marec-Berard P, et al. Among authors: schmitt c. Eur J Cancer. 2020 Jan;125:58-68. doi: 10.1016/j.ejca.2019.11.007. Epub 2019 Dec 12. Eur J Cancer. 2020. PMID: 31838406 Clinical Trial.
Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia.
Petit A, Trinquand A, Chevret S, Ballerini P, Cayuela JM, Grardel N, Touzart A, Brethon B, Lapillonne H, Schmitt C, Thouvenin S, Michel G, Preudhomme C, Soulier J, Landman-Parker J, Leverger G, Macintyre E, Baruchel A, Asnafi V; French Acute Lymphoblastic Leukemia Study Group (FRALLE). Petit A, et al. Among authors: schmitt c. Blood. 2018 Jan 18;131(3):289-300. doi: 10.1182/blood-2017-04-778829. Epub 2017 Oct 19. Blood. 2018. PMID: 29051182 Free article.
2,211 results